Perrigo's Q4 2025 Earnings: Focus on Non-GAAP Measures & Strategic Review

SEC 8-K Filing Notice

Company: Perrigo Company plc (PRGO) Filing Date: 2026-02-26 Accession Number: 0001585364-26-000006

Items Filed

Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Summary

Perrigo Company plc released its fourth-quarter earnings for the period ending December 31, 2025, via an 8-K filing with the SEC. The company's announcement emphasizes non-GAAP financial measures, which exclude items like amortization, litigation, restructuring charges, and acquisition-related costs, to provide investors and analysts with a clearer view of underlying operating trends and facilitate comparisons. Perrigo is also highlighting 'CORE' Perrigo, which excludes infant formula (currently under strategic review) and previously divested businesses, to offer a more consistent picture of its go-forward operations.

Key Takeaways

Perrigo released Q4 2025 earnings, focusing on non-GAAP financial measures.
Non-GAAP measures exclude items like amortization, litigation, and restructuring charges to improve comparability.
Company highlights 'CORE' Perrigo, excluding infant formula and divested assets, for a clearer view of ongoing operations.
Perrigo is unable to reconcile its FY2026 outlook to GAAP measures due to uncertainties surrounding non-recurring charges and restructuring.
The filing includes a press release (Exhibit 99.1) with detailed financial information.

Analysis

For investors, this filing signals Perrigo's continued focus on presenting an adjusted view of its financial performance, potentially to highlight underlying strengths amidst strategic changes like the review of its infant formula business. The inability to reconcile forward-looking non-GAAP measures to GAAP figures introduces some uncertainty, requiring investors to carefully consider the company's explanations and assumptions. Competitors will be watching Perrigo's 'CORE' performance to gauge its success in streamlining operations and focusing on key growth areas. The broader pharmaceutical market will be interested in the outcome of Perrigo's strategic review of its infant formula business, as it could signal further consolidation or shifts in that segment.

This post was automatically generated from an SEC 8-K filing.